Features | Partner Sites | Information | LinkXpress
Sign In
Demo Company

Scientists Achieve Successful Target Genome Insertion Correction in Human Hematopoietic Stem Cells

By BiotechDaily International staff writers
Posted on 17 Jun 2014
Italian scientists have accomplished an efficient zinc finger nuclease (ZFN)-mediated, targeted gene insertion that resulted in correction of the genetic defect in stem cells from an individual with X-linked severe combined immunodeficiency (SCID-X1).

Significantly, the study demonstrates that the treatment effectively targets a type of hematopoietic stem cells (HSCs) that are responsible for the long-term repopulation of the bone marrow following a transplant procedure. The data support the clinical translation of this strategy for SCID-X1, and other immunodeficiencies and monogenic diseases.

“The ability to accomplish targeted integration of a therapeutic gene into HSCs represents a major step forward in the quest for more precise and safe gene therapies,” stated Luigi Naldini, MD, PhD, director, San Raffaele Telethon Institute for Gene Therapy (TIGET; Milan, Italy), and a senior author of the study. “We used ZFNs to promote insertion of a corrective DNA sequence into the IL2RG gene in HSCs derived from either cord blood or bone marrow. This strategy enables correction of the inherited functional defect of the gene while at the same time restoring its expression under physiological control. This work should open a path to the development of safer and potentially curative treatments for SCID-X1 and, conceivably, other genetic disorders.”

The study, was conducted at TIGET by a team of scientists led by Dr. Naldini in collaboration with Sangamo scientists, and was published online May 28, 2014, in the journal Nature. Researchers exploited the fact that ZFN-mediated genome editing requires only a transient expression of the ZFNs to effect a permanent change in the genome. They used messenger RNA and electroporation to deliver the ZFNs and a non-integrating vector, an integrase-defective lentiviral vector (IDLV), to provide a corrective therapeutic DNA sequence, a so-called “donor template,” to human stem cells. This delivery approach, in combination with modified culture conditions for the cells, increased the effectiveness of gene transfer and targeted integration, especially in more primitive longer-lasting stem cells, to levels that can be used therapeutically to potentially treat a range of monogenic diseases.

The study, which included assessing the proposed gene correction strategy in vitro in HSCs derived from the bone marrow of a symptomatic four-month-old SCID-X1 patient, demonstrated the functional re-formation of the IL2RG gene in the lymphoid progeny of corrected HSCs in vivo.

“Sangamo’s ZFN gene-editing platform provides precise permanent targeted integration of therapeutic genes in contrast to conventional integrating vector approaches which insert genes randomly,” stated Philip Gregory, D. Phil., Sangamo’s senior vice president, research and chief scientific officer, and a coauthor of the study. “This work demonstrates efficient targeted gene insertion in long-term repopulating HSCs, which support multilineage differentiation in to all cells of the blood. These data support the application of ZFN-mediated gene modification across a range of monogenic diseases.”

Sangamo BioSciences, Inc. (Richmond, CA, USA) is focused on engineering genetic cures for monogenic and infectious diseases by deploying its novel DNA-binding protein technology platform in therapeutic gene regulation and genome editing. The company has ongoing phase 2 clinical trials to evaluate the safety and efficacy of a novel ZFP therapeutic for the treatment of HIV/AIDS (SB-728-T) and NGF-AAV for Alzheimer’s disease (CERE-110). Sangamo’s other therapeutic programs are focused on monogenic and rare diseases.

Related Links:

San Raffaele Telethon Institute for Gene Therapy
Sangamo BioSciences



view channel
Image: Micrograph showing immunofluorescence of skin differentiation markers for basal keratinocytes (Photo courtesy of Dr. Russ Carstens, University of Pennsylvania).

Alternate Splicing Proteins Critically Linked to Skin and Organ Development

Two proteins that regulate alternative splicing in epithelial cells have been linked to the proper development of the skin and protective layers that surround other organs in the body. Two steps are... Read more

Drug Discovery

view channel
Image: Endoscopic image of a bowel section known as the sigmoid colon afflicted with ulcerative colitis. The internal surface of the colon is blotchy and broken in places (Photo courtesy of Wikimedia Commons).

Orally Delivered Curcumin-Loaded Microparticles Effectively Treat Mouse Model of Ulcerative Colitis

Microparticles (MPs) loaded with the efficient anti-inflammatory agent curcumin were found to effectively treat a mouse model of ulcerative colitis. Ulcerative colitis is a chronic relapsing disease... Read more


view channel

Collaboration Agreement to Boost Discovery of Fully Human Antibodies for Therapeutic Use

The discovery of fully human antibodies for therapeutic use will be boosted by a recently announced collaboration between a major university research center and a dynamic biopharmaceutical development company. Regeneron Pharmaceuticals, Inc. (Tarrytown, New York, USA) and The Experimental Therapeutics Institute (ETI)... Read more


17 Oct 2015 - 21 Oct 2015
25 Oct 2015 - 29 Oct 2015
16 Nov 2015 - 19 Nov 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.